Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 9:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 203 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Psychosis and Schizophrenia Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

NCT01730781
View directory record Official record
Conditions
Schizophrenia, Cannabis Dependence, Prodromal for Psychotic Illness, Family History of Alcoholism, Healthy Control, Opioid-use Disorder, Post Traumatic Stress Disorder
Interventions
[11-C]OMAR
Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 9, 2026, 9:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Electroconvulsive Therapy in Clozapine Refractory Schizophrenia

NCT00042224
View directory record Official record
Conditions
Schizophrenia
Interventions
Electroconvulsive Therapy (ECT), Clozapine
Procedure · Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 9, 2026, 9:57 AM EDT
Completed Not applicable Interventional

Neurocognition After Perturbed Sleep

NCT05032963
View directory record Official record
Conditions
Schizophrenia
Interventions
Overnight polysomnography examinations
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 9, 2026, 9:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis

NCT04004416
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Healthy, Psychosis, Schizophreniform Disorders, Schizo Affective Disorder, Major Depression With Psychotic Features
Interventions
Placebo and fMRI, Lorazepam and fMRI
Other · Drug
Lead sponsor
University of Michigan
Other
Eligibility
16 Years to 60 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 9, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy of PEAR-004 in Schizophrenia

NCT03751280
View directory record Official record
Conditions
Schizophrenia
Interventions
PEAR-004, Sham
Device
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Garden Grove, California • Oakland, California • Torrance, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 9, 2026, 9:57 AM EDT
Completed Phase 4 Interventional Results available

D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions

NCT01981759
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Delusional Disorder
Interventions
D-Cycloserine, Placebo, Cognitive Behavioral Therapy
Drug · Other · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 68 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 9, 2026, 9:57 AM EDT
Active, not recruiting Phase 3 Interventional

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

NCT06894212
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
35
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 9, 2026, 9:57 AM EDT
Completed Not applicable Interventional

Cognitive Behavioral Social Skills Training for Improving Social Functioning in People With Schizophrenia

NCT00338975
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive Behavioral Social Skills Training (CBSST), Goal-focused supportive contact (GFSC), Social Skills Training, Goal Setting
Behavioral
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 9, 2026, 9:57 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.

NCT00790192
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone, Quetiapine XR, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
29
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 9, 2026, 9:57 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone Low-Dose - High-Dose Study Study

NCT01821378
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone, Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
28
States / cities
Little Rock, Arkansas • Cerritos, California • Escondido, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Oct 9, 2026, 9:57 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Hippocampal Response to Acute Oral Doses of CBD During an fMRI Memory Task

NCT04778644
View directory record Official record
Conditions
CBD
Interventions
CBD, Placebo
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 9, 2026, 9:57 AM EDT
Not listed No phase listed Observational

Early-Phase Schizophrenia: Practice-based Research to Improve Outcomes

NCT04004364
View directory record Official record
Conditions
First Episode Psychosis
Interventions
Coordinated Specialty Care (CSC)
Other
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
700 participants
Timeline
2020 – 2025
U.S. locations
1
States / cities
Lauderdale Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 9, 2026, 9:57 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia

NCT00549718
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
21
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 9, 2026, 9:57 AM EDT
Completed Not applicable Interventional Results available

Mobile After-Care Support App: Pilot RCT

NCT03955250
View directory record Official record
Conditions
Psychotic Disorder
Interventions
Mobile After-Care Support (MACS) app, Mobile app attention control
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 9, 2026, 9:57 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Social Isolation and Aging in Schizophrenia

NCT07419321
View directory record Official record
Conditions
Schizophrenia and Related Disorders
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
40 Years to 70 Years
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 9, 2026, 9:57 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

SV2 PET Imaging With [11C]APP311

NCT03995121
View directory record Official record
Conditions
Schizophrenia and Other Psychotic Disorders, Cannabis Use Disorder, Healthy
Interventions
[11C]APP311
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 9, 2026, 9:57 AM EDT
Completed Phase 1 Interventional

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

NCT02087579
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions
Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 9, 2026, 9:57 AM EDT
Not listed Phase 1Phase 2 Interventional

Siltuximab in Schizophrenia

NCT02796859
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Siltuximab, normal saline
Drug
Lead sponsor
Brian Miller
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 9, 2026, 9:57 AM EDT
Recruiting Phase 2 Interventional

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

NCT07459647
View directory record Official record
Conditions
Schizophrenia
Interventions
ML-007C-MA
Drug
Lead sponsor
MapLight Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
42
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 9, 2026, 9:57 AM EDT
Completed Phase 1 Interventional

A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia

NCT04510298
View directory record Official record
Conditions
Schizophrenia
Interventions
SP-624, Placebo
Drug
Lead sponsor
Sirtsei Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Garden Grove, California • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 9, 2026, 9:57 AM EDT
Completed Phase 3 Interventional

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

NCT00347425
View directory record Official record
Conditions
Schizophrenia and Schizoaffective Disorder
Interventions
Aripiprazole, Olanzapine, Risperidone, Quetiapine, Ziprasidone
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
63
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated May 21, 2008 · Synced Oct 9, 2026, 9:57 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Delta-9-THC and Iomazenil in Healthy Humans

NCT00982982
View directory record Official record
Conditions
Schizophrenia, Mental Disorders, Psychotic Disorders
Interventions
THC and Iomazenil, Placebo (control)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 9, 2026, 9:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Mobile Technology to Enhance Early Psychosis Treatment Delivery

NCT03303456
View directory record Official record
Conditions
Psychosis, Clinical High Risk for Psychosis
Interventions
Mobile health application - Ginger.io
Other
Lead sponsor
University of California, Davis
Other
Eligibility
13 Years to 30 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 9, 2026, 9:57 AM EDT
Withdrawn Phase 2 Interventional

L-arginine Study for Persistent Symptoms of Schizophrenia

NCT04054973
View directory record Official record
Conditions
Schizo Affective Disorder, Schizophrenia
Interventions
L-arginine, Sapropterin Dihydrochloride
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 9, 2026, 9:57 AM EDT